Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CMV seroprevalence and coronary CMV-DNA detection in immunocompetent patients with heart diseases.
Cento V, Colagrossi L, Bossi I, Armenia D, Nava A, Piccinelli E, Maloberti A, Inglese E, Matarazzo E, DI Ruscio F, Paba P, Marcuccilli F, Perrone M, Chiricolo G, Alteri C, Scaglione F, Vismara C, Campisi DA, Fanti D, Romeo F, Andreoni M, Oliva F, Ceccherini-Silberstein F, Giannattasio C, Perno CF. Cento V, et al. Minerva Med. 2023 Jun;114(3):289-299. doi: 10.23736/S0026-4806.22.07778-3. Epub 2022 Oct 18. Minerva Med. 2023. PMID: 36255708
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patients.
Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD; EuroSIDA Study Group. Ceccherini-Silberstein F, et al. J Infect Dis. 2007 Oct 15;196(8):1180-90. doi: 10.1086/521678. Epub 2007 Sep 19. J Infect Dis. 2007. PMID: 17955437
Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
Svicher V, Alteri C, D'Arrigo R, Laganà A, Trignetti M, Lo Caputo S, Callegaro AP, Maggiolo F, Mazzotta F, Ferro A, Dimonte S, Aquaro S, di Perri G, Bonora S, Tommasi C, Trotta MP, Narciso P, Antinori A, Perno CF, Ceccherini-Silberstein F. Svicher V, et al. Antimicrob Agents Chemother. 2009 Jul;53(7):2816-23. doi: 10.1128/AAC.01067-08. Epub 2009 Jan 5. Antimicrob Agents Chemother. 2009. PMID: 19124665 Free PMC article.
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Ceccherini-Silberstein F, Van Baelen K, Armenia D, Trignetti M, Rondelez E, Fabeni L, Scopelliti F, Pollicita M, Van Wesenbeeck L, Van Eygen V, Dori L, Sarmati L, Aquaro S, Palamara G, Andreoni M, Stuyver LJ, Perno CF. Ceccherini-Silberstein F, et al. Antimicrob Agents Chemother. 2010 Sep;54(9):3938-48. doi: 10.1128/AAC.01720-09. Epub 2010 May 17. Antimicrob Agents Chemother. 2010. PMID: 20479206 Free PMC article.
Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.
Svicher V, Alteri C, Gori C, Salpini R, Marcuccilli F, Bertoli A, Longo R, Bernassola M, Gallinaro V, Romano S, Visca M, Ursitti A, Feasi M, Micheli V, Angelico M, Cassola G, Parruti G, Gubertini G, De Sanctis GM, Ceccherini-Silberstein F, Cappiello G, Spanò A, Perno CF. Svicher V, et al. Dig Liver Dis. 2010 Dec;42(12):902-7. doi: 10.1016/j.dld.2010.04.017. Epub 2010 Jun 19. Dig Liver Dis. 2010. PMID: 20621632
324 results